Asia Pharma Launch Advisory

Faster access. Better launch decisions.

We help pharmaceutical and biotech companies accelerate decisions and execution across Asia - combining launch excellence, market access, and operator judgement to move faster, without wasted time or cost.

Timeline slipping? The gap is compounding daily.

Talk to us Explore services

22 years of senior leadership inside global biopharma with GSK · AMGEN · SANDOZ · MSD.

Successful track record launching and growing +100 molecules across 30 countries.

In-depth experience with Biologics · Vaccines · Small molecules · Generics and biosimilars.

How we operate

Asia-first

Built for the complexity of Asian pharma launches.

Senior-led

The person forming the view is the one in the room.

AI-accelerated

Hybrid workflows that compress decision cycles.

Embedded delivery

We stay focused until the access date patients feel.

Delayed launch.
Deferred benefit.

Every month between approval and access defers benefit for patients, payers, and clinicians. Novarex exists to close that gap.

Healing is a matter of time, but it is sometimes also a matter of opportunity.

Hippocrates - Precepts

01

Speed as a design choice

Speed built into the operating model. Compressed decision cycles, tighter coordination, embedded execution.

02

Senior voice, start to finish

One senior voice from diagnosis through delivery. The person forming the view is the one in the room.

03

Measured by benefit delivered

The date a better medicine reaches the patient in a form, at a cost, and through a delivery route that works.

What we deliver

Four service lines. One goal: move faster, with the decisions that matter already made. AI remains an accelerator inside the work, not a separate service line.

Launch Excellence

For teams with launch timelines at risk: align decisions, simplify coordination, and keep execution moving across Asia.

View service Talk to us

Commercial Growth

Post-launch performance focus, signal reading, and execution follow-through.

View service

Commercial Due Diligence

Operator-led diligence for investment decisions with an Asian launch component.

View service

Market Access & Pricing

Clearer pricing, reimbursement, and payer decisions across complex access environments.

View service

Asia is where growth is - and where medicines are most needed next.

The growth is real, but the region is not one market. We combine global strategy with market-specific execution discipline.

Explore Asia Focus

Growth momentum

Expanding demand, investment, and healthcare capacity across key Asian markets.

Life sciences investment

Biomedical manufacturing and regional capital flows are changing launch priorities.

Regulatory heterogeneity

Approval and access timelines rarely move together.

Coordination cost

Global, regional, and local teams often optimise differently.

Built from real-world launch pressure

Founded on senior leadership inside global biopharma, with deep expertise launching and scaling across Asia.

Talk to us Learn more about us

Global Emerging Markets

Launch planning and in-market execution across heterogeneous healthcare systems.

Pricing & Access

Payer engagement, reimbursement sequencing, and tender strategy.

Advisor Panel

Cross-functional senior depth when extra specialist support is needed.

Execution Style

Launch pace, reduced decision sets, and embedded delivery support.

Insights from the field

Four shifts reshaping how medicines reach patients - from the operator’s seat.

Let’s move faster

Tell us where you are stuck - and we will help you move forward. Timeline slipping? The gap is compounding daily. A thirty-minute call is enough to locate where the intervention lands.